

Member FINRA/SIPC

Toll-Free: 561-391-5555 ♦ www.DawsonJames.com ♦ 101 North Federal Highway - Suite 600 ♦ Boca Raton, FL 33432

Can-Fite BioPharma Ltd. (NYSE/CANF)

November 16, 2020

Jason H. Kolbert

Head of Healthcare Research

646-465-6891

jkolbert@dawsonjames.com

BUY Rated: COMFORT Advances (Psoriasis) while Acrobat Falls (RA Stops)

Can-Fite BioPharma announced that Dr. Rifaat Safadi, Principal Investigator of the Company's Phase 2 study of namodenoson in the treatment of NAFLD/NASH delivered a late-breaking oral presentation at the AASLD conference. Data presented during the oral presentation is presented below.

Investment Highlights


Where Are We in NASH? The data referenced above was presented during the oral presentation and included:

- Anti-Inflammatory effect - a significant decrease in the liver enzymes ALT and AST and significant improvement in the positive cytokine adiponectin was recorded in the Namodenoson 25 mg treated group
- Reduced liver fat content - manifested by a significant reduction in % of liver fat volume assessed by MRI-PDFF and a decrease in the Controlled Attenuation Parameter (CAP - score \geq 331) measured by FibroScan in the Namodenoson 25 mg group
- Decrease in FIB-4 and FAST - non-invasive tests showed anti-fibrosis effect in Namodenoson 25 mg group
- Decrease in body weight - a linear decrease in body weight was recorded in the 25 mg and 12.5 mg Namodenoson groups with a better effect in the higher dose
- Safety - Namodenoson continued to have a safe profile and was very well tolerated with no drug emergent severe adverse effects and no hepatotoxicity

Namodenoson in Liver Cancer – Pivotal is Next. The FDA has agreed with Can-Fite's proposed pivotal Phase 3 trial design. The study protocol and registration plan have also been submitted to the European Medicines Agency (EMA). Namodenoson is currently being used to treat liver cancer patients in a compassionate use program in Israel, which has enrolled seven patients. In addition, two patients who were enrolled in the Company's former Phase 2 study, who responded well to the drug, are continuing treatment. Those two advanced liver cancer patients have reached an overall survival of over 2.5 years while being treated with Namodenoson.

Valuation. We have removed Piclidenoson in RA but maintain it in Psoriasis, Namodenoson in HCC, and NAFLD. We apply a probability of success in these patient-based models. These metrics then flow into our valuation models. For Can-Fite, we apply a 30% discount rate, which is in addition to our therapeutic probability of success rate. We select 30% as the Company is not yet profitable, and most of the products are still dependent on the outcome of the clinical trial. Our valuation conclusion is an equally weighted average of our FCFF, EPS, and sum-of-the-parts analysis. We use a fully diluted end-year share count and assume multiple raises. The conclusion of this method is a \$5.00 price target.

Current Price	\$1.82		
Price Target	\$5.00		
Estimates	F2020E	F2021E	F2022E
Expenses (\$000s)	17,093	16,669	19,648
1Q March	4,474	3,834	4,519
2Q June	4,035	4,001	4,715
3Q September	4,211	4,334	5,108
4Q December	4,373	4,501	5,305
	F2020E	F2021E	F2022E
EPS (diluted)	(0.52)	(0.06)	(0.07)
1Q March	(0.47)	(0.01)	(0.02)
2Q June	(0.01)	(0.01)	(0.02)
3Q September	(0.02)	(0.02)	(0.02)
4Q December	(0.02)	(0.02)	(0.02)
EBITDA/Share	(\$0.15)	(\$0.16)	(\$1.08)
EV/EBITDA (x)	0.0	0.0	0.0
Stock Data			
52-Week Range	\$1.08	-	\$4.95
Shares Outstanding (mil.)	15.4		
Market Capitalization (mil.)	\$28.0		
Enterprise Value (mil.)	\$15.5		
Debt to Capital	0.0%		
Book Value/Share	\$4.52		
Price/Book	15.1		
Average Three Months Trading Volume (M)	0.6		
Insider Ownership	5.4%		
Institutional Ownership	9.2%		
Short interest (mil.)	2.2%		
Dividend / Yield	\$0.00/0.0%		



COMFORT Continues... An Independent Data Monitoring Committee recommended the Phase 3 psoriasis study continue. The IDMC also recommended that one of the dosing groups be dropped. The committee advised "no change" to the sample size, which we view as positive. Recall that the study is designed to evaluate the efficacy and safety of daily Piclidenoson, administered orally, compared to Apremilast (Otezla) and placebo in 407 patients with moderate-to-severe plaque psoriasis. The study is being conducted in five countries in Europe, Israel, and Canada. The primary endpoint is to be based on the percent of patients who achieve a PASI 75 score at week 16 vs. placebo. The secondary endpoints are to include non-inferiority vs. Otezla at week 32. Psoriasis alone is estimated to be a \$9B market.

ACROBAT stops. The IDMC has recommended the study be stopped. This study is a 24-week, 525-person four-arm (high and low dose versus MTX and placebo) trial designed to establish the drug as non-inferior to Methotrexate (MTX) in newly diagnosed patients with moderate-to-severe RA. The primary endpoint of ACROBAT is a disease activity score (DAS) after 12 weeks of treatment in patients dosed with Piclidenoson compared to those dosed with MTX. In a Phase 2b study (N=79) with Piclidenoson given twice daily, 49% of patients achieved ACR20, 19% ACR50, and 11% ACR70. The scores are comparable to MTX but with a benign AE profile. Patients have been selected for the study based on the overexpression of the A3AR biomarker. Management is evaluating next steps. We had assumed just a 50% probability of success, for now, we remove RA from our model.

Piclidenoson as a therapeutic in COVID. The trial is to assess efficacy through standard measures of clinical and respiratory status at Day 29, including the proportion of patients alive and free of respiratory failure, as well as the proportion discharged home without need for supplemental oxygen. Safety and pharmacokinetic data will also be captured.

Risk to our thesis, include the following: (1) commercial; (2) regulatory; (3) clinical; (4) manufacturing; (5) financial; (6) liability; and (7) intellectual property.

Product Modeling Assumptions

1. We assume the program in RA does not continue but Psoriasis does to a second pivotal trial. If we assume a similar size, cost, and time for the studies, it suggests we could see U.S. top line data in a year from the current trial.
2. We assume Can-Fite may partner Piclidenoson (and Namodenoson). For the purpose of our model, we assume a sliding scale royalty at a base of 25% but rising to 30% based on sales levels. In accordance with this assumption, we only moderately increase G&A expenses as the Company is not likely to build a salesforce in this scenario.
3. We assume pricing of \$5,000 in the U.S. and \$3,000 in Europe with 2% year on year increases for Piclidenoson in Psoriasis, and the target population is assumed to be high A₃AR expressers.
4. A probability success factor of 50% to our models for Psoriasis.
5. We now assume Namodenoson is approved and launches (U.S. and Europe), for late-stage liver cancer in 2024.
6. We assume Namodenoson pricing of \$50,000 in the U.S. and \$35,000 in Europe with a 2% y/y increase.
7. A probability success factor of 50% is applied to our HCC model-based, which is based on Phase 2 data.
8. A probability success factor of 10% to our U.S. and EU models for NAFLD/NASH as the current Phase 2 study is exploratory, and the clinical development pathway for this indication is long and expensive and may require a partner to pay development costs. As such, we believe it's prudent to heavily discount the indication.
9. We do not include CF 602 for the ED indication in our model as the product is still in early stages of testing. We assume a partner is needed to move the project into the clinic.
10. We do not include any estimates for COVID.

Exhibit 1. U.S. Market Model for Psoriasis

Piclidenoson - CF101 (US)	2018E	2019E	2020E	2021E	2022E	2023E	2024E	2025E	2026E	2027E	2028E	2029E	2030E
Psoriasis incidence	7,178,760	7,322,335	7,468,782	7,618,158	7,770,521	7,925,931	8,084,450	8,246,139	8,411,061	8,579,283	8,750,868	8,925,886	9,104,403
Increase in incidence	2%	2%	2%	2%	2%	2%	2%	2%	2%	2%	2%	2%	2%
Plaque psoriasis (80%)	5,743,008	5,857,868	5,975,026	6,094,526	6,216,417	6,340,745	6,467,560	6,596,911	6,728,849	6,863,426	7,000,695	7,140,709	7,283,523
Moderate to severe plaque psoriasis (17%)	976,311	995,838	1,015,754	1,036,069	1,056,791	1,077,927	1,099,485	1,121,475	1,143,904	1,166,782	1,190,118	1,213,920	1,238,199
Patients seeking treatment (84%)	820,102	836,504	853,234	870,298	887,704	905,458	923,568	942,039	960,880	980,007	999,699	1,019,693	1,040,087
Market Penetration						0.0%	3.0%	6.0%	7.0%	8.0%	9.0%	10.0%	11.0%
Patients receiving CF101						-	27,707	56,522	67,262	78,408	89,973	101,969	114,410
Annual cost of treatment						\$ 5,000	\$ 5,100	\$ 5,202	\$ 5,306	\$ 5,412	\$ 5,520	\$ 5,631	\$ 5,743
Increase in Price						2%	2%	2%	2%	2%	2%	2%	2%
Revenue ('000)						\$ -	\$ 141,306	\$ 294,029	\$ 356,893	\$ 424,356	\$ 496,687	\$ 574,170	\$ 657,103
Probability of Success						50%	50%	50%	50%	50%	50%	50%	50%
Total Revenue ('000)						\$ -	\$ 70,653	\$ 147,015	\$ 178,446	\$ 212,178	\$ 248,343	\$ 287,085	\$ 328,552

Source: Dawson James estimates, company reports

Exhibit 2. EU Market Model for Psoriasis

Piclidenoson - CF101 (EU)	2018E	2019E	2020E	2021E	2022E	2023E	2024E	2025E	2026E	2027E	2028E	2029E	2030E
Psoriasis incidence	11,548,440	11,779,409	12,014,907	12,255,297	12,500,403	12,750,411	13,005,419	13,265,528	13,530,838	13,801,455	14,077,484	14,359,034	14,646,214
Increase in incidence	2%	2%	2%	2%	2%	2%	2%	2%	2%	2%	2%	2%	2%
Plaque psoriasis (80%)	9,238,752	9,423,527	9,611,998	9,804,238	10,000,322	10,200,329	10,404,335	10,612,422	10,824,670	11,041,164	11,261,987	11,487,227	11,716,971
Moderate to severe plaque psoriasis (17%)	1,570,588	1,602,000	1,634,040	1,666,720	1,700,055	1,734,056	1,768,737	1,804,112	1,840,194	1,876,998	1,914,538	1,952,829	1,991,885
Patients seeking treatment (84%)	1,319,294	1,345,680	1,372,593	1,400,045	1,428,046	1,456,607	1,485,739	1,515,454	1,545,763	1,576,678	1,608,212	1,640,376	1,673,184
Market Penetration						0.0%	2.0%	9.0%	10.0%	11.0%	12.0%	13.0%	14.0%
Patients receiving CF101						-	29,715	136,391	154,576	173,435	192,985	213,249	234,246
Price of treatment						\$ 3,000	\$ 3,060	\$ 3,121	\$ 3,184	\$ 3,247	\$ 3,312	\$ 3,378	\$ 3,446
Increase in Price						2%	2%	2%	2%	2%	2%	2%	2%
Revenue ('000)						\$ -	\$ 90,927	\$ 425,703	\$ 492,113	\$ 563,194	\$ 639,214	\$ 720,459	\$ 807,224
Probability of Success						50%	50%	50%	50%	50%	50%	50%	50%
Total Revenue ('000)						\$ -	\$ 45,464	\$ 212,852	\$ 246,056	\$ 281,597	\$ 319,607	\$ 360,229	\$ 403,612

Source: Dawson James estimates, company reports

Exhibit 3. Income Statement

Can-Fite Biopharma: Income Statement (\$000)																																		
-YE December 31	2015A	2016A	2017A	2018A	2019A	1Q20A	2Q20E	3Q20E	4Q20E	2020E	1Q21E	2Q21E	3Q21E	4Q21E	2021E	1Q22E	2Q22E	3Q22E	4Q22E	2022E	2023E	2024E	2025E	2026E	2027E	2028E	2029E	2030E						
Revenue:																																		
Picidenoson (CF-101), Rheumatoid Arthritis U.S.	165	170	847	-	2,032	198	204	-	-	402	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-					
Picidenoson (CF-101), Rheumatoid Arthritis EU	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-					
Picidenoson (CF-101), Psoriasis U.S.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	70,653	147,015	176,446	212,178	248,343	287,085	328,552					
Picidenoson (CF-101), Psoriasis EU	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	45,464	212,852	246,056	281,597	319,607	360,229	403,612					
Namodenoson HCC U.S.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	7,940	41,304	51,567	62,592	74,424	87,110	100,699					
Namodenoson HCC EU	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	11,095	57,716	72,057	87,463	103,996	121,722	140,711					
Namodenoson NASH/NAFLD U.S.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	81,284	169,135	263,953	366,155	380,948	396,338	412,350					
Namodenoson NASH/NAFLD EU	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	67,654	140,775	219,653	304,755	317,071	329,883	343,883					
Total Product Sales	165	170	847	-	2,032	198	204	-	-	402	-	-	-	-	-	-	-	-	-	-	-	-	124,057	401,170	476,070	556,367	642,375	734,424	832,863					
Milestone From Gebro Holdings	-	-	-	3,820	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-				
Picidenoson (CF-101), Rheumatoid Arthritis U.S.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-				
Royalty Rate from Global Partnership	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-			
Picidenoson (CF-101), Rheumatoid Arthritis EU	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-			
Royalty Rate from Global Partnership	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-			
Picidenoson (CF-101), Psoriasis U.S.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-			
Royalty Rate from Global Partnership	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-		
Picidenoson (CF-101), Psoriasis EU	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-		
Royalty Rate from Global Partnership	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-		
Namodenoson HCC U.S.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-		
Royalty Rate from Global Partnership	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Namodenoson HCC EU	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Royalty Rate from Global Partnership	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Namodenoson NASH/NAFLD U.S.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Royalty Rate from Global Partnership	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Namodenoson NASH/NAFLD EU	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Royalty Rate from Global Partnership	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total royalties, collaborative revenue	-	-	-	4,452	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Total Revenue	-	170	847	4,452	2,032	198	204	-	-	402	-	-	-	-	-	-	-	-	-	-	-	-	60,406	157,460	221,311	293,439	344,036	376,360	414,897					
Expenses:																																		
Partnership Costs including COGS	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Research and Development	3,858	6,081	5,285	6,075	10,976	3,771	3,283	2,911	3,023	11,196	2,626	2,741	2,969	3,083	11,419	2,679	2,795	3,028	3,145	11,648	11,881	12,118	12,361	12,608	12,860	13,117	13,380	13,647						
General and Administrative	2,725	2,726	2,956	3,159	3,059	703	752	1,300	1,350	5,000	1,208	1,260	1,365	1,418	5,250	1,840	1,920	2,080	2,160	8,000	12,000	12,600	13,230	13,892	14,586	15,315	16,081	16,885						
Total Expenses	6,583	8,807	8,241	9,234	14,035	4,474	4,035	4,211	4,373	17,093	3,834	4,001	4,334	4,501	16,669	4,519	4,715	5,108	5,305	19,648	23,881	30,921	45,649	50,303	55,265	60,551	66,182	72,176						
Operating Income (Loss)	(6,418)	(8,637)	(7,394)	(5,414)	(12,003)	(4,276)	(3,831)	(4,211)	(4,373)	(16,691)	(3,834)	(4,001)	(4,334)	(4,501)	(16,669)	(4,519)	(4,715)	(5,108)	(5,305)	(19,648)	(23,881)	(29,485)	(45,649)	(50,303)	(55,265)	(60,551)	(66,182)	(72,176)						
Finance expenses	564	178	1,102	1,204	893	(66)	(62)	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-		
Finance income	(1,920)	(1,820)	(2,999)	(51)	3,109	(66)	(62)	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-		
Total Other Income	(1,356)	(1,642)	(1,897)	1,153	2,416	(66)	(62)	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-		
Pre-tax Income	5,066	(6,955)	(4,963)	(6,571)	(9,587)	(4,342)	(3,769)	(4,211)	(4,373)	(16,691)	(3,834)	(4,001)	(4,334)	(4,501)	(16,669)	(4,519)	(4,715)	(5,108)	(5,305)	(19,648)	(23,881)	(29,485)	(45,649)	(50,303)	(55,265)	(60,551)	(66,182)	(72,176)						
Taxes on income	4	29	-	4	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-		
Adjustments arising from translating financial statements of foreign operations	-	9	30	-	-	(715)	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-		
Remeasurement loss from defined benefit plans	99	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-		
Tax Rate	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	5%	8%	12%	25%	30%	32%	34%					
GAAP Net Income (Loss)	5,066	(6,956)	(4,993)	(6,571)	(9,587)	(4,342)	(3,769)	(4,211)	(4,373)	(16,691)	(3,834)	(4,001)	(4,334)	(4,501)	(16,669)	(4,519)	(4,715)	(5,108)	(5,305)	(19,648)	(23,881)	(29,485)	(45,649)	(50,303)	(55,265)	(60,551)	(66,182)	(72,176)						
Total comprehensive loss	5,066	(6,957)	(4,993)	(6,571)	(9,587)	(4,342)	(3,769)	(4,211)	(4,373)	(16,691)	(3,834)	(4,001)	(4,334)	(4,501)	(16,669)	(4,519)	(4,715)	(5,108)	(5,305)	(19,648)	(23,881)	(29,485)	(45,649)	(50,303)	(55,265)	(60,551)	(66,182)	(72,176)						
GAAP-EPS	#DIV/0!	(0.25)	(0.14)	(0.17)	(1.77)	(0.47)	(0.24)	(0.25)	(0.16)	(0.97)	(0.14)	(0.15)	(0.16)	(0.12)	(0.56)	(0.12)	(0.13)	(0.14)	(0.14)	(0.53)	(0.64)	0.78	2.96	4.51	6.25	7.41	8.13	8.89						
GAAP-EPS (Dil)	-	(0.14)	(0.16)	(0.16)	(1.35)	(0.31)	(0.24)	(0.23)	(0.13)	(0.83)	(0.12)	(0.12)	(0.13)	(0.10)	(0.47)	(0.10)	(0.11)	(0.12)	(0.12)	(0.45)	(0.55)	0.68	2.55	3.89	5.40	6.40	7.02	7.68						
Wght Avg ADR Shrs (Bas) - '000s	-	28,096	32,994	38,793	5,833	9,222	15,413	17,133	27,151	17,230	27,176	27,205	27,232	37,259	29,718	37,297	37,334	37,371	37,409	37,353	37,502	37,652	37,803	37,955	38,107	38,259	38,413	38,567						
Wght Avg ADR Shrs (Dil) - '000s	-	28,096	32,994	41,953	8,910	13,833	15,413	17,985	33,003	20,059	33,036	33,069	33,103	43,136	35,586	43,179	43,222	43,265	43,308	43,244	43,417	43,591	43,765	43,941	44,117	44,293	44,471	44,649						

Risk Analysis

In addition to the typical risks associated with development stage specialty pharmaceutical companies, potential risks specific to Can-Fite are as follows:

Financial risk. The Company may need to raise capital in the marketplace, and there can be no assurances that the Company will be able to successfully raise capital and or do so on favorable terms.

Clinical and regulatory risk. Lead products must start and complete clinical trials. Trials may not produce results sufficient for regulatory approval.

Partnership risk. Can-Fite may seek partnerships for clinical development support and commercialization. We have no specific knowledge of any discussions with possible partners today, and there can be no assurances that the Company will be able to secure a favorable partnership.


Commercial risk. There are no assurances that the Company will be able to secure favorable pricing, commercially launch products, and achieve significant market share to become profitable.

Legal and intellectual property risk. The Company may have to defend its patents and technical know-how, and there can be no assurances that the patents will not be infringed or will be held as valid if challenged, and or that the Company may infringe on third parties' patents.

Companies mentioned in this report:

Important Disclosures:

Price Chart:



Price target and rating changes over the past three years:

- Initiated – Buy – December 13, 2018 – Price Target \$7
- Update – Buy – March 26, 2019 – Price Target \$6
- Update – Buy – May 21, 2019 – Price Target \$9 (adjusted down after reverse stock split).
- Update – Buy – August 7, 2019 – Price Target \$9
- Update – Buy – September 11, 2019 – Price Target \$9
- Update – Buy – September 18, 2019 – Price Target \$9
- Update – Buy – September 23, 2019 – Price Target \$9
- Update – Buy – October 15, 2019 – Price Target \$9
- Update – Buy – October 31, 2019 – Price Target \$9
- Update – Buy – November 4, 2019 – Price Target \$9
- Update – Buy – December 2, 2019 – Price Target \$9
- Update – Buy – December 11, 2019 – Price Target \$9
- Update – Buy – February 3, 2020 – Price Target \$9
- Update – Buy – February 19, 2020 – Price Target \$9
- Update – Buy – March 5, 2020 – Price Target \$9
- Update – Buy – April 13, 2020 – Price Target \$9
- Update – Buy – April 20, 2020 – Price Target \$9
- Update – Buy – May 19, 2020 – Price Target \$9
- Update – Buy – June 1, 2020 – Price Target \$9
- Update – Buy – June 9, 2020 – Price Target \$9
- PT Change – Buy – June 10, 2020 – Price Target lowered from \$9 to \$7.0
- Update – Buy – June 30, 2020 – Price Target \$7
- Update – Buy – July 30, 2020 – Price Target \$7
- Update – Buy – August 31, 2020 – Price Target \$7
- PT Change – Buy – October 6, 2020 – Price Target \$5
- Update – Buy – November 16, 2020 – Price Target \$5

Dawson James Securities, Inc. (the "Firm") is a member of the Financial Industry Regulatory Authority ("FINRA") and the Securities Investor Protection Corporation ("SIPC").

The Firm does not make a market in the securities of the subject Company (s). The Firm has NOT engaged in investment banking relationships with CANF in the prior twelve months, as a manager or co-manager of a public offering and has NOT received compensation resulting from those relationships. The Firm may seek compensation for investment banking services in the future from the subject Company (s). The Firm has received other compensation from the subject Company (s) in the last 12 months for services unrelated to managing or co-managing of a public offering.

Neither the research analyst(s) whose name appears on this report nor any member of his (their) household is an officer, director or advisory board member of these companies. The Firm and/or its directors and employees may own securities of the Company (s) in this report and may increase or decrease holdings in the future. As of October 31, 2020, the Firm as a whole did not beneficially own 1% or more of any class of common equity securities of the subject company(s) of this report. The Firm, its officers, directors, analysts or employees may affect transactions in and have long or short positions in the securities (or options or warrants related to those securities) of the Company (s) subject to this report. The Firm may affect transactions as principal or agent in those securities.

Analysts receive no direct compensation in connection with the Firm's investment banking business. All Firm employees, including the analyst(s) responsible for preparing this report, may be eligible to receive non-product or service-specific monetary bonus compensation that is based upon various factors, including total revenues of the Firm and its affiliates as well as a portion of the proceeds from a broad pool of investment vehicles consisting of components of the compensation generated by investment banking activities, including but not limited to shares of stock and/or warrants, which may or may not include the securities referenced in this report.

Although the statements in this report have been obtained from and are based upon recognized statistical services, issuer reports or communications, or other sources that the Firm believes to be reliable, we cannot guarantee their accuracy. All opinions and estimates included in this report constitute the analyst's judgment as of the date of this report and are subject to change without notice.

Information about valuation methods and risks can be found in the "VALUATION" and "RISK ANALYSIS" sections of this report.

The securities of the Company discussed in this report may be unsuitable for investors depending on their specific investment objectives and financial position. This report is offered for informational purposes only and does not constitute an offer or solicitation to buy or sell any securities discussed herein in any jurisdiction where such would be prohibited. Additional information is available upon request.

Rating Definitions:

- 1) **Buy:** the analyst believes the price of the stock will appreciate and produce a total return of at least 20% over the next 12-18 months;
- 2) **Neutral:** the analyst believes the price of the stock is fairly valued for the next 12-18 months;
- 3) **Sell:** the analyst believes the price of the stock will decline by at least 20% over the next 12-18 months and should be sold.

The following chart reflects the range of current research report ratings for all companies followed by the analysts of the Firm. The chart also reflects the research report ratings relating to those companies for which the Firm has performed investment banking services.

Ratings Distribution	Company Coverage		Investment Banking	
	# of Companies	% of Total	# of Companies	% of Totals
Market Outperform (Buy)	22	81%	4	18%
Market Perform (Neutral)	5	19%	1	20%
Market Underperform (Sell)	0	0%	0	0%
Total	27	100%	5	19%

Analyst Certification:

The analyst(s) whose name appears on this research report certifies that 1) all of the views expressed in this report accurately reflect his (their) personal views about any and all of the subject securities or issuers discussed; and 2) no part of the research analyst's compensation was, is, or will be directly or indirectly related to the specific recommendations or views expressed by the research analyst in this research report; and 3) all Dawson James employees, including the analyst(s) responsible for preparing this research report, may be eligible to receive non-product or service specific monetary bonus compensation that is based upon various factors, including total revenues of Dawson James and its affiliates as well as a portion of the proceeds from a broad pool of investment vehicles consisting of components of the compensation generated by investment banking activities, including but not limited to shares of stock and/or warrants, which may or may not include the securities referenced in this report.